Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walton Taylor

Surgery Dallas, TX Medical Doctor

NPI 1063455533 CMS profile 93848

7777 Forest Ln Ste C204, Dallas, TX 75230

Open in the dashboard

General payments

$369,060

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Walton Taylor of Dallas, TX is reported in the CMS Open Payments database as having received $369,060 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,678 13
2024 General $39,595 18
2023 General $42,709 15
2022 General $44,091 11
2021 General $63,034 14
2020 General $76,404 12
2019 General $60,548 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walton Taylor
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Walton Taylor were reported at $42,678. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Walton Taylor Surgery median Middle half National median
2019 $60,548 $253 $82–$1,521 $163
2020 $76,404 $131 $40–$706 $114
2021 $63,034 $168 $50–$904 $132
2022 $44,091 $224 $76–$1,218 $149
2023 $42,709 $253 $82–$1,255 $160
2024 $39,595 $279 $90–$1,381 $164
2025 $42,678 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ImpediMed, Inc. $315,539 12 payments
  2. iCAD, Inc $46,789 17 payments
  3. Heron Therapeutics, Inc. $1,900 1 payment
  4. Leica Microsystems Inc. $1,694 2 payments
  5. Endomagnetics Ltd $1,187 6 payments
  6. Myriad Genetic Laboratories, Inc. $471 10 payments
  7. Stryker Corporation $177 3 payments
  8. Merck Sharp & Dohme Corporation $173 7 payments
  9. AxoGen $145 1 payment
  10. Hologic, LLC $143 1 payment
  11. Other $842 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $363,025 24 payments
  2. Food and Beverage $4,367 70 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $1,668 1 payment
Products named General payments · program years 2019–2025
  1. Mammography-Powerlook AMP $26,250 7 payments
  2. AXXENT SURFACE CONTROLLER $20,539 10 payments
  3. HTX-011 $1,900 1 payment
  4. Magseed Surgical Oncology $1,169 5 payments
  5. Magtrace Surgical Oncology $618 4 payments
  6. myRisk Oncology $296 6 payments
  7. myRisk Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis $175 4 payments
  8. MOLLI $161 2 payments
  9. Magseed Breast and Skeletal Health $143 1 payment
  10. Magtrace Breast and Skeletal Health $143 1 payment
  11. Other $1,128 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

145

Median for General Surgery: 59

Drug cost

$1,105

Median for General Surgery: $393

Branded share of claims

64.1%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 93 $516
Doxycycline Hyclate Generic 20 $329
Anastrozole Generic 11 $145
Cephalexin Generic 21 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$97,368

Medicare's payments for the services billed

Medicare patients

206

Average age 76

Services billed

812

113 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Cancer 40%
Ischemic heart disease 31%
Chronic kidney disease 29%
Diabetes 25%
Depression 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $72
$72 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record